Multiple sites in Spain have begun enrolling patients in the DuraGraft coronary artery bypass grafting (CABG) European Registry. The registry will evaluate Somahlution’s flagship product, DuraGraft, a vascular graft treatment intended to improve long-term clinical outcomes following CABG surgery.
“We are looking forward to participating in the DuraGraft registry. Any opportunity to improve graft patency must be studied and considered so that we may improve long-term outcomes for CABG patients”
The first patient enrolled in Spain was treated at Hospital De Cruces Barakaldo, Bilbao. “We are looking forward to participating in the DuraGraft registry. Any opportunity to improve graft patency must be studied and considered so that we may improve long-term outcomes for CABG patients,” says the site’s principal investigator José Ignacio Aramendi Gallardo, Cardiac Surgeon. In addition to Hospital De Cruces Barakaldo, Bilbao, Hospital Ramon y Cajal and Hospital Gregorio Marañon (both in Madrid) and Complejo Hospitalario Universitario de Santiago de Compostela (Santiago de Compostela) have enrolled patients in the Spanish registry.
Patients undergoing CABG only or CABG plus valve surgery will be able to participate in this Registry. For these patients, baseline clinical and angiographic characteristics, as well as certain procedural and post-op clinical events will be recorded. Clinical outcomes will be assessed post CABG through hospitalisation, at 30 days, and annually up to five years.
DuraGraft is a vascular graft treatment designed to improve clinical outcomes by reducing the incidence of complications of graft failure. DuraGraft is CE marked in Europe, but not yet commercially available in the USA.